| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Letters to the Editor |
1 Department of Urology, and
2 Department of Internal Medicine II, Oncology and Hematology, University Hospital Charité, Humboldt University Berlin, Schumannstrasse 20/21, D-10098 Berlin, Germany
aAuthor for correspondence. Fax 49-30-450-515-904; e-mail monika.jung{at}charite.de.
To the Editor:
Cell-free DNA in serum and plasma has been suggested to have diagnostic potential because associations between DNA concentrations and several disorders have been described (1). The concentration of cell-free DNA circulating in plasma and serum has been analyzed in several studies and used as an interchangeable index of the quantity of circulating DNA in blood (2)(3)(4). However, it is known that the DNA concentration in serum is 
3- to 24-fold higher than in plasma (3)(4)(5)(6). Recently published articles in this journal showed that various preanalytical factors of blood sampling and processing can affect the DNA concentration in plasma (5)(7)(8), but these findings do not explain the difference between plasma and serum concentrations of DNA mentioned above. Comparative investigations of the preanalytical conditions influencing the DNA concentration in serum and plasma are lacking. In addition, reference intervals for the concentration of cell-free DNA in serum were established without considering these factors (9). Thus, to complement the data of Lui et al. (5), we analyzed the influence of time delay in blood processing for plasma and serum at room temperature and at 4 °C.
Venous blood samples from 10 healthy volunteers (5 females and 5 males; mean age, 42 years) were simultaneously collected in Monovette plastic tubes without any additive for native serum (cat. no. 02.1726.001; Sarstedt), in plastic tubes with kaolin-coated plastic granulate coagulation accelerator (cat. no. 04.1904.001; Sarstedt) for preparation of serum samples, and in Monovette plastic tubes coated with potassium EDTA (cat. no. 05.1167.001; Sarstedt) for preparation of plasma samples. The tubes were either centrifuged at 2000g for 10 min at 4 °C immediately after venipuncture or were stored for 2, 4, or 8 h at room temperature (25 °C) and at 4 °C for 8 and 24 h, respectively, before being centrifuged under similar conditions. The supernatants were carefully removed and centrifuged again at 16 000g for 10 min at 4 °C and stored at -80 °C until analysis.
Using a NucleoSpin Blood Kit (Macherey-Nagel), we extracted DNA from 400 µL of sample per column, eluted it in 100 µL of buffer according to the manufacturer’s instructions, and stored the eluted DNA at -20 °C until use. DNA equivalents were quantified by amplifying the ß-globin gene by real-time PCR (LightCyclerTM Roche), using the QuantiTect SYBR Green PCR Kit (Qiagen). A 110-bp fragment of the ß-globin gene was generated with the forward primer 5'-ACACAACTGTGTTCACTAGC-3' and the reverse primer 5'-CAACTTCATCCACGTTCACC-3' (TIB MolBiol) in a final concentration of 0.5 µM each. The cycle conditions were as follows: initial activation step at 95 °C for 15 min, followed by 45 cycles of denaturation at 95 °C for 15 s, annealing at 56 °C for 20 s, and extension at 72 °C for 15 s. The reaction volume was 20 µL, including 2 µL of DNA eluate. The product-specific melting temperature was 82 °C. A calibration curve obtained with serial dilutions of a control DNA template (LightCycler Control Kit DNA; Roche) was linear at least up to 4546 genome-equivalents of ß-globin [genome-equivalents/mL were calculated using a conversion factor of 6.6 pg of DNA per single diploid human cell (5)].
The within-run (n = 12) and between-run (n = 10) imprecisions (CVs) for a DNA template (807.6 genome-equivalents/mL) were 3.1% and 7.2%, respectively. Statistical analyses were made with GraphPad Prism 3.03 for Windows (GraphPad Software). Parametric statistical tests were used because the DNA concentrations in our 10 samples had a gaussian distribution (Kolmogorov–Smirnov test).
There was no difference in the mean DNA concentrations (P = 0.729, paired t-test) in paired serum samples prepared with or without coagulation accelerator. We therefore compared the DNA concentrations in EDTA plasma with those in serum samples obtained in tubes without clot activation additive (Fig. 1
). The DNA concentration in plasma did not change when blood samples were stored at room temperature for 8 h or at 4 °C for 24 h before being processed (Fig. 1
). These results correspond to observations of Lui et al. (5), who analyzed the DNA concentrations during a 6-h interval after phlebotomy. Our data (Fig. 1
) confirm the observation that the DNA concentration is higher in serum than in plasma, as also shown by others (3)(4)(5)(6).
|
The time delay and the storage temperature of blood before centrifugation had a significant impact on the DNA concentration in serum (Fig. 1
). Compared with the DNA concentrations in plasma samples prepared immediately after venipuncture (0 h at room temperature), the DNA concentrations in serum samples were 2.3-fold higher when blood was stored for 0 h at room temperature and 8 h at 4 °C before centrifugation. The DNA concentration in serum increased 3.8- to 4.8-fold when blood was stored for 2–8 h at room temperature and 3-fold when blood was stored at 24 h at 4 °C compared with plasma values (0 h at room temperature).
DNA in serum rather than plasma has been reported to provide improved sensitivity for the detection of liver metastases in patients with colorectal carcinoma (4). This observation and our data indicate that the quantification of free circulating DNA in serum can be of diagnostic value only if the effect of time delay between blood collection and serum preparation is taken into account. When the serum DNA concentration is used as a potential marker for clinical disorders, strict standardization of serum preparation is mandatory. Reference intervals published recently obviously did not take this into consideration (9).
Acknowledgments
This work was supported in part by grants from the SONNENFELD-Stiftung Berlin. The study contains results of the doctoral thesis of M.L.
References
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  I. Lavon, M. Refael, B. Zelikovitch, E. Shalom, and T. Siegal Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades Neuro Oncology, February 1, 2010; 12(2): 173 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Goldshtein, M. J Hausmann, and A. Douvdevani A rapid direct fluorescent assay for cell-free DNA quantification in biological fluids Ann Clin Biochem, November 1, 2009; 46(6): 488 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hohaus, M. Giachelia, G. Massini, G. Mansueto, B. Vannata, V. Bozzoli, M. Criscuolo, F. D'Alo, M. Martini, L. M. Larocca, et al. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas Ann. Onc., August 1, 2009; 20(8): 1408 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bernal, F. Aguayo, C. Villarroel, M. Vargas, I. Diaz, F. J. Ossandon, E. Santibanez, M. Palma, E. Aravena, C. Barrientos, et al. Reprimo as a Potential Biomarker for Early Detection in Gastric Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6264 - 6269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Bastian, G. S. Palapattu, S. Yegnasubramanian, X. Lin, C. G. Rogers, L. A. Mangold, B. Trock, M. Eisenberger, A. W. Partin, and W. G. Nelson Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy Clin. Cancer Res., September 15, 2007; 13(18): 5361 - 5367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Umetani, A. E. Giuliano, S. H. Hiramatsu, F. Amersi, T. Nakagawa, S. Martino, and D. S.B. Hoon Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum J. Clin. Oncol., September 10, 2006; 24(26): 4270 - 4276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sozzi, L. Roz, D. Conte, L. Mariani, F. Andriani, P. Verderio, and U. Pastorino Effects of Prolonged Storage of Whole Plasma or Isolated Plasma DNA on the Results of Circulating DNA Quantification Assays J Natl Cancer Inst, December 21, 2005; 97(24): 1848 - 1850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Tamkovich, O. E. Bryzgunova, E. Yu. Rykova, V. I. Permyakova, V. V. Vlassov, and P. P. Laktionov Circulating Nucleic Acids in Blood of Healthy Male and Female Donors Clin. Chem., July 1, 2005; 51(7): 1317 - 1319. [Full Text] [PDF]
|
|
|
|
|
|
M. Frattini, D. Balestra, P. Verderio, G. Gallino, E. Leo, G. Sozzi, M. A. Pierotti, and M. G. Daidone Reproducibility of a Semiquantitative Measurement of Circulating DNA in Plasma From Neoplastic Patients J. Clin. Oncol., May 1, 2005; 23(13): 3163 - 3164. [Full Text] [PDF]
|
|
|
|
|
|
G. Sozzi, D. Conte, and L. Roz In Reply: J. Clin. Oncol., May 1, 2005; 23(13): 3164 - 3165. [Full Text] [PDF]
|
|
|
|
|
|
N. Y.L. Lam, T. H. Rainer, R. W.K. Chiu, and Y.M. D. Lo EDTA Is a Better Anticoagulant than Heparin or Citrate for Delayed Blood Processing for Plasma DNA Analysis Clin. Chem., January 1, 2004; 50(1): 256 - 257. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) or 4 °C (
) are indicated on the x axis. a and b indicate the significances, calculated by the Dunnett multiple-comparison test after parametric ANOVA analysis with repeated measures: a, at least P <0.05 vs DNA in plasma samples processed immediately after collection; b, at least P <0.05 vs DNA in serum samples processed immediately after collection.